

Innovation in Breast Cancer

iBC 2024

15th · 16th Feb
2024

VIRTUAL **FORMAT**



Miguel Martín Jiménez

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Miguel Martín is a Medical Oncologist based in Madrid, Spain. Since 1990, he is fully devoted to breast cancer research and treatment. He is a Professor of Medicine at the Complutense University and currently Head of Medical Oncology Service (Hospital General Universitario Gregorio Marañón, Madrid). He received his medical degree at the University of Valladolid and completed his fellowship and residency at the San Carlos University Hospital, Madrid. In 1989 he obtained the European Certification on Medical Oncology (London). His areas of research include systemic treatment in all stages of breast cancer, where he has participated and led many national and international clinical trials. In 1990-1991 Prof. Martín visited the Fred Hutchinson Cancer Research Center and the University of Washington Medical Center de Seattle (EEUU), where he worked on high-dose chemotherapy with bone marrow transplantation for breast cancer. Editor of several medical journals, he was member of the International Editorial Board of the journal *Lancet Oncology*, as well as other international journals (*European Journal of Clinical & Medical Oncology*, *Cancer & Chemotherapy Reviews*). In 1995, Prof. Martín created GEICAM (Spanish Group for Breast Cancer Research), a network involving more than 140 Spanish institutions and, since its foundation, he is the Chairman of the Group. GEICAM has carried out more than 120 clinical, translational and epidemiological studies in breast cancer. Since 2001, Prof. Martín serves as a member of the Board of Directors and of the Scientific Steering Committee of TRIO, an international not-for-profit clinical research organization involving 45 different countries. He has published more than 250 articles in peer-reviewed medical journals, being first or corresponding author of original papers published in *New England Journal of Medicine*, *Journal of Clinical Oncology*, *Journal of the National Cancer Institute*, *Lancet Oncology*, *Seminars in Oncology*, *British Journal of Cancer*, *The Oncologist*, and *Annals of Oncology* among others. He has contributed to more than 300 presentations at international medical meetings and has presented invited lectures in several countries around the world. He is a full member of several scientific societies: ASCO, ESMO, SEOM, ASBD, EBMT, ABMT and MASCC. Prof. Martín was the Spanish representative at ESMO from 2003 till 2006. In 2006, he was appointed European Liaison of the International Affairs Committee of ASCO. He has served as a member of the panel of the International Consensus Conference of Early Breast Cancer (St Gallen) and is currently a member of the Steering Committee of Early Breast Cancer Trialists Cooperative Group (Oxford, UK). In 2012, Dr Martín was nominated Advisor of the Spanish Ministry of Health. He was nominated Board Member of The National Committee Of The Spanish Society Medical Oncology (2013). In June 2014 he has been named reviewer of the ANEP. In March 2015, Prof. Miguel Martín has been named Numerary Academic by the Spanish Medical Surgery Academy. Since October 2015 to December 2017, Dr. Martín held the position of President of the Spanish society of medical oncology. Dr. Martín holds the 2017 ESMO Award as Breast Cancer Expert and his contribution to medical oncology development. 2018 Honorary Award for Excellence in the Scientific Trajectory from AstraZeneca Foundation.

Publications

1 Scientific paper. Martín, M.; Zielinski, C.; Ruiz-Borrego, M.; et al; Gil-Gil, M. 2021. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL ANNALS OF ONCOLOGY. ELSEVIER. 32-4, pp.488-499. ISSN 0923-7534, ISSN 1569-8041.

2 Scientific paper. Mayer, Erica L.; Dueck, Amylou C.; Martín, Miguel; et al; Gnant, Michael. 2021. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study LANCET ONCOLOGY. ELSEVIER SCIENCE INC. 22-2, pp.212-222. ISSN 1470-2045, ISSN 1474-5488.

3 Scientific paper. Litton, J. K.; Hurvitz, S. A.; Mina, L. A.; et al; Etil, J. 2020. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial ANNALS OF ONCOLOGY. ELSEVIER. 31-11, pp.1526-1535. ISSN 0923-7534, ISSN 1569-8041.

4 Scientific paper. Slamon, Dennis J.; Neven, Patrick; Chia, Stephen; et al; Jerusalem, Guy. 2020. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer NEW ENGLAND JOURNAL OF MEDICINE. MASSACHUSETTS MEDICAL SOC. 382-6, pp.514-524. ISSN 0028-4793, ISSN 1533-4406.

5 Scientific paper. Coleman, Robert; Finkelstein, Dianne M.; Barrios, Carlos; et al; Chan, Arlene. 2020. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial LANCET ONCOLOGY. ELSEVIER SCIENCE INC. 21-1, pp.60-72. ISSN 1470-2045, ISSN 1474-5488.

6 Scientific paper. Delaloge, S.; Cella, D.; Ye, Y.; et al; Martín, M. 2019. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial ANNALS OF ONCOLOGY. OXFORD UNIV PRESS. 30-4, pp.567-574. ISSN 0923-7534, ISSN 1569-8041.

Innovation in Breast Cancer

iBC 2024

15th · 16th Feb
2024

VIRTUAL **FORMAT**

7 Scientific paper. Pernas, Sonia; Martin, Miguel; Kaufman, Peter A.; et al; Cortes, Javier. 2018. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial LANCET ONCOLOGY. ELSEVIER SCIENCE INC. 19-6, pp.812-824. ISSN 1470-2045, ISSN 1474-5488.

8 Scientific paper. Martin, M.; Campone, M.; Bondarenko, I; et al; Aapro, M.2018. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane ANNALS OF ONCOLOGY. OXFORD UNIV PRESS. 29-5, pp.1195-1202. ISSN 0923-7534, ISSN 1569-8041.

9 Scientific paper. Hurvitz, Sara A.; Martin, Miguel; Symmans, W. Fraser; et al; Slamon, Dennis. 2018. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial LANCET ONCOLOGY. ELSEVIER SCIENCE INC. 19-1, pp.115-126. ISSN 1470-2045, ISSN 1474-5488.

10 Scientific paper. Martin, Miguel; Holmes, Frankie A.; Ejlertsen, Bent; et al; ExteNET Study Grp. 2017. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial LANCET ONCOLOGY. ELSEVIER SCIENCE INC. 18-12, pp.1688-1700. ISSN 1470-2045, ISSN 1474-5488.

11 Martin, Miguel. 2018. The LILAC trial and the blooming of anticancer biosimilars LANCET ONCOLOGY. 19-7, pp.861-863. ISSN 1470-2045, ISSN 1474-5488.

Participation in R&D and Innovation projects

1 FAITH: A Federated Artificial Intelligence solution for monitoring mental health status after cancer treatment H2020 Convocatoria SC1-DTH-2019.. (WATERFORD INSTITUTE OF TECHNOLOGY – WIT. HGUGM-SERMAS (Collaborator Center)). 2020-2023. 4.831.233 €.

2 Predictive value of the mutational load in tumor, plasma and circulating tumor cells on the response to neoadjuvant docetaxel and carboplatin combination in triple negative breast cancer patients (PI18/01775) Instituto de Salud Carlos III. (Hospital General Universitario Gregorio Marañón). 07/2018-12/2020. 196.020 €.

3 Circulating tumor cells (CTCs) as early predictor of survival and response to treatment in patients with locally advanced metastatic pancreatic cancer after the first cycle of chemotherapy SEOM. Andrés Muñoz Martín. (Hospital General Universitario Gregorio Marañón). 01/2018-01/2020. 15.000 €.

4 Triple Negative breast cancer: predicting response to neoadjuvant docetaxel-carboplatin through TILs characterization and immune signatures based in massive RNA-sequencing (PI15/00117) Instituto de Salud Carlos III. Miguel Martín Jimenez. (Hospital General Universitario Gregorio Marañón). 2016-2018. 231.715 €.

5 PROSIGNA TEST AS ROUTINE CLINICAL PRACTICE IN DIFFERENT SUBTYPES OF BREAST CANCER DIAGNOSTIC Celgene and Universidad de Alcalá de Henares. Miguel Martín Jimenez. (Hospital General Universitario Gregorio Marañón). 2017-2017. 6.000 €.

Participation in R&D and Innovation contracts

Patents

1 Molpeceres Álvarez, Carlos Luis; Lauzurica Santiago, Sara; Márquez Fernández, Andrés; Muñoz Martín, David; Morales Furió, Miguel; Colina Brito, Mónica; Martín Jiménez, Miguel; Ramos Medina, Rocío; Muñoz Martín, Andrés; Gayarre Navarro, Javier; Massarrah Sánchez, Tatiana; Del Monte Millán, María. PCT/ES2018/070064. "Método para seleccionar, manipular y aislar células tumorales circulantes en líquidos corporales por transferencia asis da por láser" Spain. 29/01/2018. Fundación para la Investigación Biomédica del Hospital Gregorio Marañón and Universidad Politécnica de Madrid (FIBHGM and UPM).

2 Perou; Bernard; Nielson; Ellis; Parker; Martín; Carrasco; Caballero. PCT/US2012/067317. Methods of treating Breast Cancer with Taxane Therapy Spain. 30/11/2012. Nanostring Technologies, Inc.. GEICAM Reference (40448-513001WO).